MarketPulse

GLP-1 therapies

3 articles
The Motley FoolThe Motley Fool··Adam Spatacco

Novo Nordisk's 72% Crash: Generational Buying Opportunity or Dangerous Trap?

Novo Nordisk's 72% crash from peaks sparks debate: value trap or buying opportunity amid GLP-1 market competition from Eli Lilly.
LLYNVOVKTXvaluation compressionmarket opportunity
BenzingaBenzinga··Vandana Singh

UnitedHealth Crushes Earnings, Raises 2026 Guidance Amid Medicare Coverage Headwinds

UnitedHealth raises 2026 earnings guidance above $18.25 per share after Q1 beat. Stock rises 3.2% despite overbought signals and Medicare drug coverage challenges.
UNHXLVTMEDEAGLoverbought conditionsearnings beat
BenzingaBenzinga··Namrata Sen

Eli Lilly Stockpiles $1.5B in Experimental Weight-Loss Drug Ahead of FDA Review

Eli Lilly stockpiles $1.5B of experimental weight-loss drug orforglipron ahead of expected April FDA approval decision, signaling management confidence.
LLYNVOFDA approvalpharmaceutical competition